drugset / Trial / NCT00881127

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions

NCT00881127

Phase 1 Completed 40 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg ER tablets under fasting conditions.

Timeline

Start
2005-07
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetirizine Other / unclassified 5 mg
Subject Pseudoephedrine Small molecule 120 mg

Indications